Somewhat Favorable News Coverage Somewhat Unlikely to Affect CareFusion (CFN) Stock Price

News stories about CareFusion (NYSE:CFN) have been trending somewhat positive on Saturday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CareFusion earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the healthcare company an impact score of 46.4660388277976 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

CareFusion (NYSE CFN) remained flat at $$59.94 during trading on Friday. The firm has a market cap of $12,240.00 and a P/E ratio of 25.51.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect CareFusion (CFN) Stock Price” was published by Equities Focus and is the property of of Equities Focus. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at

About CareFusion

CareFusion Corporation is a global medical technology company. The Company operates in two business segments: Medical Systems and Procedural Solutions. The Company’s primary product brands include: Alaris intravenous (IV) infusion systems; Pyxis and Rowa automated medication dispensing and supply management systems; AVEA, Vela and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus, MaxZero, SmartSite and Texium needle-free IV infusion valves, administration sets and accessories; V.

Receive News & Ratings for CareFusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareFusion and related companies with's FREE daily email newsletter.

Leave a Reply